Indeed, our data also showed that knockdown of c-Myc significantly reduced the cell viability of DLD-1 (Fig. 1D) and HCT116 cells (Fig. 1E), suggesting that inhibiting c-Myc is a pragmatic therapeutic approach for treating late-stage CRC. The gene discussed is MYC; the disease is colorectal carcinoma.